Hydroxocobalamin Versus Methylene Blue for Vasoplegic Syndrome in Cardiothoracic Surgery: A Retrospective Cohort

被引:21
|
作者
Furnish, Craig [1 ]
Mueller, Scott W. [1 ]
Kiser, Tyree H. [1 ]
Dufficy, Lisa [2 ]
Sullivan, Breandan [3 ]
Beyer, Jacob T. [4 ]
机构
[1] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA
[2] Univ Colorado Hosp, Aurora, CO USA
[3] Univ Colorado, Sch Med, Aurora, CO USA
[4] Denver Hlth Med Ctr, Denver, CO USA
关键词
vasoplegic syndrome; vasoplegia; methylene blue; hydroxocobalamin; cardiothoracic surgery; anesthesia; COBALT TOXICITY; MANAGEMENT; RESCUE; RISK;
D O I
10.1053/j.jvca.2020.01.033
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Objective: To compare methylene blue with hydroxocobalamin as a rescue therapy for vasoplegic syndrome. Design: Retrospective cohort. Setting: Academic medical center. Participants: Patients undergoing cardiothoracic surgery treated for vasoplegic syndrome. Interventions: Thirty-five patients were treated with methylene blue (n = 16) or hydroxocobalamin (n = 19). Measurements and Main Results: Mean arterial pressure, systemic vascular resistance, and vasopressor exposures were recorded before and after medication administration. Change in time-averaged norepinephrine equivalents in the hour after administration was the primary outcome. The average norepinephrine equivalent observed at baseline in this cohort was 0.347 mu g/kg/min. Methylene blue patients had greater Acute Physiological Assessment and Chronic Health Evaluation II scores (29.8 v 22.2; p = 0.01) and trended toward greater European System for Cardiac Operative Risk Evaluation II values (26.8% v 15.1%; p = 0.07). Methylene blue and hydroxocobalamin were associated with increased mean arterial pressure and systemic vascular resistance 1 hour after administration (10.6 mmHg and 192 dyn*sec/cm(5); p = 0.01 and p = 0.01, respectively; 11.8 mmHg and 254 dyn*sec/cm(5); p = 0.002 and p = 0.015, respectively). Hemodynamic changes were not different between the rescue therapy groups (p = 0.79 and p = 0.53, respectively). No significant differences were observed within the 1-hour change in time-averaged norepinephrine equivalents for either agent or when methylene blue and hydroxocobalamin were compared (0.012 +/- 0.218 mu g/kg/min v -0.037 +/- 0.027 mu g/kg/min; p = 0.46, respectively). When compared with baseline time-averaged norepinephrine equivalent (0.326 +/- 0.106 mu g/kg/min), only hydroxocobalamin was associated with decreased vasopressor requirements at the 1-hour (0.255 +/- 0.129 mu g/kg/min; p = 0.03) and 4-hour time points (0.247 +/- 0.180 mu g/kg/min; p = 0.04) post-administration. Conclusion: Methylene blue and hydroxocobalamin increased mean arterial pressures and systemic vascular resistance without significantly decreasing time-averaged norepinephrine exposure in the hour after administration. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:1763 / 1770
页数:8
相关论文
共 50 条
  • [1] Hydroxocobalamin or Methylene Blue for Vasoplegic Syndrome in Adult Cardiothoracic Surgery
    Kram, Shawn J.
    Kram, Bridgette L.
    Cook, Jennifer C.
    Ohman, Kelsey L.
    Ghadimi, Kamrouz
    [J]. JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2022, 36 (02) : 469 - 476
  • [2] METHYLENE BLUE DOSE RESPONSE FOR VASOPLEGIC SYNDROME IN ADULT CARDIOTHORACIC SURGERY
    Kram, Shawn
    Kram, Bridgette
    Cook, Jennifer
    Ohman, Kelsey
    Ghadimi, Kamrouz
    [J]. CRITICAL CARE MEDICINE, 2022, 50 (01) : 193 - 193
  • [3] Intraoperative Versus Postoperative Hydroxocobalamin for Vasoplegic Shock in Cardiothoracic Surgery
    Khandekar, Divya A.
    Seelhammer, Troy G.
    Mara, Kristin C.
    Stephens, Elizabeth H.
    Wittwer, Erica D.
    Wieruszewski, Patrick M.
    [J]. JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2023, 37 (12) : 2538 - 2545
  • [4] Methylene Blue Monotherapy Compared With Combination Therapy With Hydroxocobalamin for the Treatment of Refractory Vasoplegic Syndrome: A Retrospective Cohort Study
    Feih, Joel T.
    Rinka, Joseph R. G.
    Zundel, Michael T.
    [J]. JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2019, 33 (05) : 1301 - 1307
  • [5] Intravenous methylene blue versus hydroxocobalamin as treatment for intraoperative vasoplegic syndrome in liver transplant patients
    Pai, S. -L
    Logvinov, I
    Argevani, L.
    Aniskevich, S.
    [J]. TRANSPLANTATION, 2019, 103 (08) : 122 - 123
  • [6] Hydroxocobalamin Versus Methylene Blue for the Treatment of Vasoplegic Shock Associated With Cardiopulmonary Bypass
    Hiruy, Aklil
    Ciapala, Stephanie
    Donaldson, Chase
    Wang, Lu
    Hohlfelder, Benjamin
    [J]. JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2023, 37 (11) : 2228 - 2235
  • [7] Methylene Blue for Vasoplegic Syndrome Postcardiac Surgery
    Habib, Aly Makram
    Elsherbeny, Ahmed Galal
    Almehizia, Rayd Abdelaziz
    [J]. INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2018, 22 (03) : 168 - 173
  • [8] TREATMENT OF REFRACTORY VASOPLEGIC SHOCK WITH HYDROXOCOBALAMIN AND METHYLENE BLUE
    Feih, Joel
    Rinka, Joseph
    Zundel, Michael
    Kaiser, Markus
    [J]. CRITICAL CARE MEDICINE, 2016, 44 (12)
  • [9] Methylene Blue for Vasoplegic Syndrome
    Booth, Alexander T.
    Melmer, Patrick D.
    Tribble, J. Benjamin
    Mehaffey, J. Hunter
    Tribble, Curt
    [J]. HEART SURGERY FORUM, 2017, 20 (05): : E234 - E238
  • [10] EVALUATION OF HYDROXOCOBALAMIN COMPARED TO METHYLENE BLUE FOR VASOPLEGIA POST-CARDIOTHORACIC SURGERY
    Barker, Nicholas
    Busse, Laurence
    Owenby, Sarah
    [J]. CRITICAL CARE MEDICINE, 2020, 48